Login to Your Account



Biogen Idec Inc. and Schering AG

Ibritumomab tiuxetan; monoclonal antibody targeting CD20, combined with radioisotope

To continue reading subscribe now to BioWorld Phase III Report

Learn More about BioWorld Phase III Report

Already a subscriber? Sign In or Buy now to activate your subscription